Compare Enbridge Inc (ENB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Zimmer Biomet Holdings Inc — how do they compare? Enbridge Inc trades at $46.6 (market cap $103.38B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Enbridge Inc is far larger — about 6.1× Zimmer Biomet Holdings Inc's market cap, and Enbridge Inc pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 91 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| ENB | ZBH | |
|---|---|---|
Market Cap | $103.38B | $16.95B |
Volume | 3,684,305 | 2,505,240 |
Sector | Energy | Health |
52-Week High | $58.04 | $103.98 |
52-Week Low | $45.23 | $79.58 |
Typical Hold Time | 91 Days | 89 Days |
Enterprise Value | $185.39B | $24.02B |
Dividend Yield | 6.02% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $46.54, up 1.42% on the day, with a bearish technical signal from moving averages. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.46 surpassing the $0.43 estimate. The company maintains a solid dividend yield, with a $0.97 payment scheduled for September 2026. Revenue grew to $65.19B in 2025, and net income reached $7.49B, though profit margins have fluctuated. Analyst consensus is mixed, with a $61.63 price target suggesting significant upside from current levels.
The outlook for ENB is cautiously optimistic, supported by earnings beats and a strong dividend, but tempered by bearish technicals and rising debt levels. Investment appeal lies in its stable cash flows and growth backlog, while risks include interest rate sensitivity and execution of capital projects. The stock presents a value opportunity if it can navigate macroeconomic headwinds and maintain operational performance.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.
The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
